Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an
attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic
pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and
Saltikva).
Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV
metastatic pancreatic cancer will significantly prolong the overall survival and prolong the
time to disease progression.
Patient Population: unresectable, metastatic pancreatic cancer patients 18 years of age or
older